13G Filing: Adage Capital Management and Intec Pharma Ltd (NTEC)

Item 3.

IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

(a)

¨

Broker or dealer registered under Section 15 of the Act;

(b)

¨

Bank as defined in Section 3(a)(6) of the Act;

(c)

¨

Insurance company as defined in Section 3(a)(19) of the Act;

(d)

¨

Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)

¨

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

¨

An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);

(g)

¨

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)

¨

A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act;

(i)

¨

A church plan that is excluded from the definition
of an investment company under Section 3(c)(14) of the Investment Company Act;

(j)

¨

A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

(k)

¨

Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please

specify the type of institution: Not applicable.

Item 4.		OWNERSHIP
	A.	Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
			(a)	Amount beneficially owned: 1,725,000
			(b)	Percent of class: 6.64%. The percentages set forth in this Schedule 13G are calculated based upon the 25,962,706 Ordinary Shares reported to be issued and outstanding in the Company’s Prospectus filed pursuant to Rule 424(b)(5), filed with the Securities and Exchange Commission on August 17, 2017 after giving effect to the completion of the offering, as described therein, and the Issuer’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on August 21, 2017.

13G Filing: Adage Capital Management and Intec Pharma Ltd (NTEC)

Published on August 25, 2017 at 3:52 pm by Insider Monkey Staff in Hedge Funds

Page 8 of 12 – SEC Filing

Follow Intec Pharma Ltd.

Follow Intec Pharma Ltd.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

Item 2(d).	TITLE OF CLASS OF SECURITIES
	Ordinary Shares, no par value (the “Ordinary Shares“).

Item 2(e).	CUSIP NUMBER
	The Ordinary Shares have no CUSIP number. The CINS number for the Ordinary Shares is M53644106.